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very simple ancestor is a matter of taste. Presumably there is an as-yet not understood upper ''speed limit'' for such rates, but Lee and colleagues [6] point out that even the most elevated rates recovered do not seem to go over the limit for known rapid periods of either morphological or molecular evolution. As a result, one can indeed have one's evolutionary cake and eat it -it is possible to squeeze the radiation of the animals into a short period of time just before and during the Cambrian without having to invoke any peculiar non-Darwinian mechanisms to explain it.
Of course, this raises a further and potentially even more interesting question about how the elevated rates of gene and morphological evolution are related to each other. Lee et al. [6] , perhaps wisely, steer clear of addressing this fraught issue directly, and indeed previous attempts at examining it have come to conflicting conclusions [17, 18] . However, the mere observation that both rates are elevated is unlikely to be coincidental, and suggests that, contrary to various developmental scenarios where large-scale morphological change in the Cambrian explosion is driven by a few changes in some key developmental genes, there must be an ecological basis to it that would naturally link the two rates. The discovery that some molecular evolutionary rates are elevated during a particular interval of time will naturally re-awaken some of the vexatious issues around selection versus neutrality in molecular evolution [19] . If there is a true correlation between the two rates, this could come about by a variety of means [20] , not all of which involve direct causality. Exploring the relationship between the two will in future work surely add valued ammunition to fire at the many problems presented by early animal evolution. 10 [3] . Given the crucial role played by mTORC1 in cell growth and proliferation, these intriguing findings have fueled interest in better understanding the elusive mechanism of action of rapamycin. Extensive studies have revealed that mTORC1 phosphorylation substrates are not equally impacted by rapamycin treatment [4, 5] , suggesting that they might be regulated by additional factors (e.g., other kinases or phosphatases) and/or that a rapamycin-resistant form of mTORC1 may exist. This conundrum has been partly solved by a recent study by Kang et al. [6] , which found that the inherent capacity of a phosphorylation site to serve as an mTORC1 substrate is a key determinant of its sensitivity to rapamycin ( Figure 1 ). In other words, the authors suggest that the insensitivity of certain mTORC1 phosphorylation sites partly results from the incomplete inhibition of mTORC1 by rapamycin and the persistence of phosphorylation, rather than from the presence of a rapamycin-insensitive form of mTORC1. However, one possible alternative explanation is that rapamycin may be more potent at inhibiting substrates that require the FKBP12-rapamycin-binding (FRB) domain for their recruitment to mTORC1, as recently suggested by the crystal structure of mTOR [7] .
Before we explore these recent findings in more detail, a little background on mTORC1 substrates and their differential regulation by rapamycin is in order. mTORC1, which is composed of mTOR, Raptor and mLST8, controls cell growth in part through two downstream substrates -the ribosomal S6 kinases (S6Ks) and the eukaryotic translation initiation factor 4E (eIF4E)-binding proteins (4E-BPs) [8] . One of the S6K isoforms, S6K1, plays important roles in cell growth, proliferation and differentiation by regulating different aspects of translational control, cell cycle progression and metabolism [9] . Therefore, aberrant activation of S6K1 is a key contributor to the progression of tumors, diabetes and obesity [10] , and S6K1 inhibition increases lifespan and reduces the incidence of age-related pathologies [11] . The 4E-BPs appear to have the most profound effect on protein synthesis downstream of mTORC1, as they bind to the cap-binding protein eIF4E and thereby prevent cap-dependent translation [8] . The phosphorylation of the 4E-BPs by mTORC1 stimulates their release from eIF4E, allowing translation initiation to proceed. Similar to the S6Ks, the 4E-BPs were shown to play roles in neoplastic growth and proliferation [12] and were also found to be critical regulators of lifespan and aging [13] . Recent phosphoproteomics studies have identified several putative mTORC1 substrates, including growth factor receptor-bound protein 10 (Grb10), which functions as a negative regulator of growth factor signaling [14, 15] . To this list of bona fide mTORC1 substrates can be added PRAS40 and ULK1, which were found to regulate mTORC1 activity and autophagy, respectively. There is little doubt that many more mTORC1 substrates exist, including the RNA-binding proteins LARP1 and PATL1 [6, 14, 15] , but the function and regulation of these proteins remain to be characterized.
While rapamycin has been an indispensable tool for investigating the role of mTORC1, its biological effect varies widely between cell types. In yeast, the effect of rapamycin is much more pronounced than in mammals, as it suppresses protein synthesis by nearly 80% [5] . These differences suggested at the time that mTORC1 activity may be less important in mammalian cells; however, the discovery of ATP-competitive mTOR inhibitors and the finding that they more significantly inhibit protein synthesis in mammalian cells corrected this view. Instead, it was thought that mTORC2 or a rapamycin-insensitive form of mTORC1 may explain the reduced response to rapamycin. The fact that ATP-competitive mTOR inhibitors were found to have similar Figure 1 . The quality of mTORC1 phosphorylation sites determines their sensitivity to rapamycin and to starvation from nutrients and growth factors.
As reported in Kang et al. [6] , mTORC1 phosphorylation sites that are poor in vitro substrates (e.g., S6K1 Thr389) tend to be more sensitive to rapamycin treatment and to starvation from nutrients and growth factors. Conversely, phosphorylation sites that are good in vitro substrates of mTORC1 (e.g., 4E-BP1 Thr37 and Thr46) appear insensitive to rapamycin treatment because the partial mTORC1 inhibition is not sufficient to result in their complete dephosphorylation.
effects in cells that do not have functional mTORC2 (i.e., cells deleted for Sin1 or Rictor) gave support to the latter possibility. At a molecular level, S6K1 activity and its phosphorylation at Thr389 is known to be sensitive to rapamycin in most cell types [16] . However, the site-specific regulation of 4E-BP1 phosphorylation is much more complex and appears to be differentially regulated by rapamycin treatment. While rapamycin treatment leads to the rapid dephosphorylation of Ser65 and Thr70 on 4E-BP1, Thr37 and Thr46 were shown to be mostly insensitive to rapamycin in many cell types [4] . The finding that ATP-competitive mTOR inhibitors and Raptor depletion result in the complete dephosphorylation of both S6K1 and 4E-BP1 led to the suggestion that Thr37 and Thr46 may be regulated by a rapamycin-insensitive form of mTORC1, a view that has now been re-evaluated in the recent study by Kang et al. [6] . By introducing subtle mutations into bona fide mTORC1 phosphorylation sites, the authors were able to show that certain sites considered to be rapamycin-sensitive, such as Thr389 in S6K1, become more resistant to rapamycin treatment. Using mTORC1 in vitro kinase assays and short synthetic peptides encompassing single mTORC1 phosphorylation sites, the authors were able to see a correlation between better in vitro substrates of mTORC1 (i.e., substrates of high quality) and their insensitivity to rapamycin. These results suggest that the apparent insensitivity of mTORC1 phosphorylation sites may be due to the fact that stronger mTORC1 inhibition is required to observe their dephosphorylation. These differences are visible at the level of individual sites and not full-length proteins because substrates such as 4E-BP1 have both rapamycin-sensitive and rapamycin-resistant sites. Interestingly, the authors found that rapamycin-insensitive sites were also less sensitive to nutrient and growth factor starvation, suggesting that intrinsic differences between mTORC1 substrates, and more particularly between their phosphorylation sites, may help to coordinate the cellular response to starvation. These findings add to our understanding of the multiple mechanisms by which rapamycin ineffectiveness or resistance may occur in many cancer types. While these findings provide an explanation as to why certain mTORC1 substrates are differentially affected by rapamycin treatment, some important questions remain regarding why substrates such as 4E-BP1 appear to be rapamycin sensitive in some cell types but not in others. Are there other factors involved in substrate quality and/or rapamycin's inhibitory potency that are dependent on the cellular context? Could FKBP12 protein levels be limiting in some cell types but not in others? To overcome weaker effects and incomplete inhibition of mTORC1 by allosteric inhibitors (e.g. rapamycin and rapalogs), ATP-competitive mTOR inhibitors that potently and comprehensively block mTOR have been developed [3] . Although these inhibitors show a stronger effect than rapamycin on tumor progression, recent studies using a panel of over 600 cancer cell lines show that a large portion of cell lines (40% in the case of colorectal cancer) are resistant to these inhibitors, and this resistance is correlated with the inability of these inhibitors to block 4E-BP1 phosphorylation [17, 18] . As suggested by Kang et al. [6] , phosphorylation of mTORC1 substrates is subject to multiple regulatory mechanisms that extend far beyond the simple sequence motif of each phosphorylation site. In the case of 4E-BP1, which is regarded as a point of convergence of various signaling pathways [19] , it is possible that there are other kinases cooperating with mTORC1 to regulate its phosphorylation. We have recently shown that GSK3b phosphorylates 4E-BP1 at Thr37 and Thr46 and thereby decreases its association with eIF4E [20] , suggesting that the regulation of mTORC1 substrates may be multifactorial and thus highly dependent on the cellular context. Indeed, it is plausible to assume that cancer cells adapt by deregulating additional kinases, such as GSK3b, that substitute for mTORC1 in the phosphorylation and inactivation of some mTORC1 substrates, such as 4E-BP1.
Since its isolation in 1975, rapamycin has been used for its immunosuppressive and anti-cancer properties. Rapamycin and the rapalogs have also received recent attention because of their potential in the management of diabetes, lifespan and neurological disorders [3] . The recent report by Kang et al. [6] refines our understanding of mTORC1 and its substrates, and helps understand the molecular mechanisms that underlie rapamycin resistance. Considering the biological and clinical significance of rapamycin, these insights will likely help in the design of more potent therapeutic strategies for a number of human diseases.
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Chromosome Segregation: Learning to Let Go To ensure accurate chromosome segregation, cohesion between sister chromatids must be released in a controlled manner during mitosis. A new study reveals how distinct centromere populations of the cohesin protector Sgo1 are regulated by microtubule attachments, cyclin-dependent kinases, and the kinetochore kinase Bub1.
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Dividing cells must convey the correct complement of chromosomes to their offspring. Eukaryotes accomplish this by maintaining cohesion between replicated sister chromatids until chromosomes are bi-oriented on the mitotic spindle. Only once this has been accomplished are the attachments between chromatids released, allowing them to be sorted accurately to opposite poles of the dividing cell. Clearly then, although sister chromatids may be inseparable at first, they must learn to let go when the time comes. A report from Liu, Jia and Yu in this issue of Current Biology [1] provides new insight into this process that may have broader implications for our understanding of inner centromere function.
Cohesion between sister chromatids is maintained by cohesin complexes, together with regulators such as Sororin [2] . In vertebrate mitosis, cohesin is removed from chromosomes in two steps. In prophase, a mechanism involving phosphorylation of cohesin and Sororin by mitotic kinases removes the bulk of cohesin from chromosome arms (Figure 1 ). Cohesin at centromeres, however, is protected by Sgo1-PP2A phosphatase complexes that counteract phosphorylation of cohesin and Sororin [3] [4] [5] . To fully separate chromatids at anaphase, the remaining cohesin is cleaved by the protease Separase [2] . This raises the question of how cleavage of centromeric cohesin is limited to anaphase. A simple possibility is that Separase only becomes active at anaphase, and that Sgo1 does not protect cohesin from cleavage in mitosis. However, it has been reported that Sgo1, when inappropriately maintained at inner centromeres, prevents Separase-mediated cohesin cleavage [6] . Also, at least in budding yeast, Sgo1-PP2A complexes may inhibit Separase more directly [7] . Therefore, it is important to understand how the localization and activity of Sgo1 are regulated.
During prophase in mammalian cells, Sgo1 is found at inner centromeres (defined here as the area between the chromatin regions that contain centromeric histone CENP-A; Figure 1 ). As chromosomes become bi-oriented, Sgo1 appears to move outwards, relocating to two regions roughly coinciding with CENP-A-containing chromatin underlying kinetochores [1, 6, 8] . This movement of Sgo1 away from cohesin complexes located at inner centromeres might render cohesin susceptible to cleavage by Separase, and would provide a way to make removal of cohesin favorable only when chromosomes are correctly bi-oriented and microtubules exert tension across sister kinetochores [6] . How this relocation of Sgo1 is controlled, however, has been unknown.
A number of ways to recruit Sgo1 to centromeres have been reported, but the relative contributions of these pathways are debated. It is widely accepted that Sgo1 is brought to centromeres when histone H2A is phosphorylated at Thr-120 (H2AT120ph) by the kinetochore kinase Bub1 [9, 10] , though the structural basis for this recruitment is unknown. Sgo1 can also bind to the heterochromatin protein HP1, which itself binds chromatin by recognizing histone H3 trimethylated on Lys-9 (H3K9me3) [11] . Although most HP1 is removed from chromosomes during mitosis, a small population remains at inner centromeres that could recruit Sgo1. However, other studies have found that key H3K9 methyltransferases are not required for HP1 or Sgo1 localization in mitosis [12, 13] , and that HP1 binds to mitotic centromeres via the chromosomal passenger complex (CPC) in a manner that excludes HP1 binding to Sgo1 [14] . An alternative potential contribution to inner centromere Sgo1 localization is binding to cohesin itself, an interaction that depends on phosphorylation of Sgo1 at Thr-346 by cyclin-dependent kinases (Cdk) [5] . How do these proposed mechanisms act together to control Sgo1 function?
Although the dependency of Sgo1 localization on Bub1 activity is largely unquestioned, the reason that centromeric cohesion depends on Bub1 is less clear [15, 16] . Bub1 is a mitotic checkpoint protein, and lowering Bub1 levels might lead to
